Get Results, Every Time.
OmniSeq MSI NGS is a focused, simple and cost-effective method for clinicians to accurately assess MSI status for their patients.
OmniSeq MSI NGS delivers microsatellite instability results from tumor only FFPE samples.
Eliminate the hassle to acquire and track matched normal DNA from tissue or blood.
Use MSI by NGS to identify appropriate patients for KEYTRUDA®, regardless of histology.
Polymerase Chain Reaction
Get results every time. PCR requires normal tissue, NGS does not.1
NGS examines more markers than PCR and may increase the sensitivity of the test for non-CRC samples.2
Omniseq MSI NGS is cost equivalent to PCR, with similar turnaround times.
Immunohistochemistry Mismatch Repair
Molecular Methods (PCR or NGS)
Molecular MSI tests may deliver fewer false positives than IHC.3
IHC interpretation is qualitative and subject to variation from lab to lab.3
IHC+ / PCR- samples have lower response rates than MSI-H samples.4
- Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med. 2018 Mar;7(3):746-756
- Salipante SJ, Scroggins SM, Hampel HL, Turner EH, Pritchard CC. Microsatellite instability detection by next generation sequencing. Clin Chem. 2014; 60:1192–9
- Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn. 2008;10:293–300
- Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017 Sep;18(9):1182-1191